Skip to main content
Egyptian Journal of Medical Human Genetics

Table 2 Non-susceptibility* of the study isolates to carbapenems according to clinical breakpoints of CLSI (CLSI 2022) and screening ECOFFs [8.9]

From: Detection of intestinal colonization by carbapenem-resistant Enterobacteriaceae (CRE) among patients admitted to a tertiary care hospital in Egypt

Carbapenem

CRE by CLSIa,b

Possible Carbapenemase Producers by ECOFFs c

Total CPE isolates

Ertapenem

35(97.2%)

36 (100%)

36 (100%)

Meropenem

28 (77.8%)

36 (100%)

 36 (100%)

Imipenem

29 (80.6%)

29 (80.6%)

 36 (100%)

  1. *Non-susceptible isolates including resistant and intermediate isolates
  2. aERT ertapenem, MEM meropenem, IPM imipenem
  3. bFollowing Clinical laboratory Standards Institute (CLSI) breakpoints [8]
  4. cFollowing epidemiological cut off points (ECOFFs) [9]
Back to article page